Neuralink

Zoom

Neuralink

Neuralink doesn't have a traditional revenue model yet — it's still in clinical trials. The near-term plan is medical devices sold to hospitals and clinics for treating neurological conditions.

Brain-computer interfaces for paralysis, ALS, blindness, and other conditions would be reimbursed by insurance and healthcare systems, similar to cochlear implants or deep brain stimulators.

The long-term vision is consumer neurotechnology — healthy people choosing to get brain implants for enhanced cognition, communication, or AI interaction. This is years or decades away and faces massive regulatory and ethical hurdles.

But if it works, the total addressable market is literally every human brain on the planet.

The surgical robot is potentially a separate revenue stream. Even if the implant itself doesn't dominate, the precision robotics technology developed for neural surgery could be licensed to other medical device companies.

Neuralink has also built custom chip fabrication capabilities that could have applications beyond brain interfaces.

Zoom

Zoom uses a freemium model. Free accounts get unlimited one-on-one meetings and 40-minute group meetings.

Paid plans start at $13.33/month per user for Pro (meetings up to 30 hours), $18.33/month for Business, and custom pricing for Enterprise. Zoom also charges for add-ons — Zoom Phone (cloud phone system), Zoom Rooms (conference room hardware), and Zoom Contact Center.

The free tier is the hook. The 40-minute limit on group calls creates just enough friction to push power users to pay.

And once one person in a company pays, the whole team follows because nobody wants to be the one whose meetings keep getting cut off.

Neuralink

Elon Musk had been talking about brain-computer interfaces publicly since at least 2016. His stated motivation was existential: if AI becomes superintelligent, humans need a way to merge with it or risk becoming irrelevant.

The solution, in his mind, was a direct neural link between the human brain and computers.

Neuralink was quietly incorporated in July 2016 in California. Musk recruited a team of eight co-founders — neuroscientists, engineers, and chip designers from institutions like UC Berkeley, MIT, and Lawrence Livermore National Laboratory.

The founding team included Ben Rapoport, a neurosurgeon who understood both the medical and engineering sides, and Dongjin Seo, who had done PhD research on neural dust (tiny wireless brain sensors).

The company operated in stealth for two years before a 2019 presentation where Musk revealed the vision: a coin-sized device implanted in the skull containing thousands of ultra-thin electrode threads inserted into the brain by a custom-built surgical robot. The threads are thinner than a human hair — roughly 5 microns wide — and each one contains multiple electrodes that read neural signals.

The robot was necessary because no human surgeon could place threads that thin without damaging brain tissue.

Zoom

Eric Yuan grew up in Tai'an, a mining city in Shandong province, China. In the mid-1990s he was in his twenties and inspired by the internet boom happening in America.

He applied for a US visa. He was rejected.

He applied again. Rejected again.

Eight times in total over about two years before he was finally approved in 1997. He moved to Silicon Valley with barely any English and joined WebEx as one of its first engineers.

Yuan spent 14 years at WebEx, eventually becoming VP of Engineering. Cisco acquired WebEx in 2007 for $3.2 billion.

Yuan watched Cisco slowly bloat the product with enterprise features while the core video quality deteriorated. He kept telling Cisco leadership they needed to rebuild the product from scratch.

They kept saying no.

In 2011, Yuan quit and took 40 WebEx engineers with him. He founded Zoom Video Communications with a simple thesis: video meetings should just work.

No downloads. No lag.

No "can you hear me?" No IT department required. He built the product that Cisco refused to build.

Neuralink

Neuralink's growth strategy is the classic Musk playbook: start with the premium use case that justifies the cost, then scale down. Phase 1 is medical — treat severe neurological conditions where no other option exists.

Quadriplegia, ALS, locked-in syndrome. Patients who literally cannot move or speak are willing to undergo experimental brain surgery.

The FDA granted Breakthrough Device designation in 2020, and the first human trial (PRIME study) began in 2024.

Phase 2 is expanding medical indications — blindness, depression, epilepsy, Parkinson's. Each new condition multiplies the patient population and the regulatory pathway, building clinical evidence along the way.

Phase 3 — the moonshot — is consumer enhancement. Musk has described this as "conceptual telepathy," where you think a message and it sends.

This phase requires proving extraordinary safety over years of medical use first. Nobody is going to electively implant a brain chip unless the medical version has been proven safe for a decade.

Zoom

Zoom grew on one thing: it worked. In a world where every video call started with five minutes of technical issues, Zoom calls just connected.

That reliability was the entire marketing strategy for the first five years.

The freemium model did the rest. Teachers, coaches, therapists, book clubs, and small teams all started on the free tier.

When they hit the 40-minute limit, enough of them converted to paid. And every free meeting was essentially a demo — everyone in the meeting saw how good Zoom was.

Yuan obsessed over simplicity. While competitors like WebEx and GoToMeeting required downloads, plugins, and IT involvement, Zoom worked in the browser with one click.

The learning curve was essentially zero. Your grandmother could figure it out.

That turned out to be extremely important when a pandemic suddenly required your grandmother to figure it out.

Then COVID happened. In March 2020, the world shut down.

Every meeting — work, school, family, doctor, church, happy hour — moved to video. Zoom was already the easiest option.

Daily participants exploded from 10 million to 300 million in four months. The stock went from $70 to $588.

Neuralink

The FDA and regulatory approval process is the primary bottleneck. Brain implants are Class III medical devices — the highest risk category.

Every design change, every new indication, requires extensive clinical data. The USDA also investigated Neuralink in 2022 for potential animal welfare violations in their primate testing program, which created PR headaches.

Long-term biocompatibility is an unsolved problem. The brain treats any foreign object as an invader and forms scar tissue around it, which can degrade signal quality over time.

Making an implant that works reliably for decades inside a hostile biological environment is one of the hardest engineering problems in medicine. Neuralink's thread retraction issue in their first human patient — where some threads pulled away from the brain — highlighted how much work remains.

Talent retention has been rocky. Max Hodak, the original president, left in 2021.

Several founding scientists departed. Working for Musk is notoriously demanding, and the timeline pressure on a medical device company clashes with the inherent need for cautious, methodical development.

Zoom

The post-pandemic hangover has been severe. Zoom's stock peaked at $588 in October 2020 and crashed to under $70 by 2022 — an 88% drop.

The company went from the most exciting tech stock on the planet to a cautionary tale about pandemic valuations. Revenue growth slowed from 300%+ to single digits as people returned to offices and competitors caught up.

Security and "Zoombombing" were early crises. In early 2020, as millions of new users flooded in, trolls discovered they could join open Zoom meetings and share offensive content.

Schools, churches, and AA meetings were disrupted. It turned out Zoom's encryption wasn't truly end-to-end as advertised.

Yuan had to halt all feature development for 90 days and focus exclusively on security fixes. It was a near-death reputational crisis.

Competition from Microsoft Teams and Google Meet intensified. Both companies bundled video calling for free into products that hundreds of millions of people already used.

Microsoft Teams integrated directly into Office 365. Google Meet was built into Gmail.

Zoom had to compete against free products from two of the richest companies on Earth.

Neuralink

The N1 Implant — a coin-sized device (23mm diameter, 8mm thick) implanted flush with the skull containing a custom chip that wirelessly transmits neural data to external devices via Bluetooth. The R1 Robot — a precision surgical system that inserts 64 flexible threads carrying 1,024 electrodes into the brain with micron-level accuracy, avoiding blood vessels using computer vision.

The N1 User App — software that translates neural signals into computer commands, allowing users to control cursors, keyboards, and eventually robotic limbs through thought alone. BCI Software Platform — the signal processing and machine learning stack that decodes raw brain signals into intended actions.

Zoom

Zoom Meetings is the core — video calls that actually work. Zoom Webinars handles large-scale events with up to 50,000 attendees.

Zoom Phone is a full cloud-based phone system replacing traditional office phones. Zoom Rooms turns physical conference rooms into one-click video meeting spaces.

Zoom Contact Center competes with established call center software. Zoom Team Chat is their Slack/Teams competitor.

Zoom Whiteboard is a collaborative digital canvas. Zoom Revenue Accelerator uses AI to analyze sales calls.

And Zoom AI Companion summarizes meetings and drafts messages.

Neuralink

Elon Musk has been the primary funder, investing hundreds of millions of his personal wealth. The company raised $205 million in a Series C in 2021, then $280 million in a Series D in 2023 led by Founders Fund (Peter Thiel's firm).

A 2024 round reportedly valued the company at $8.9 billion. Google Ventures (GV) and DFJ Growth have also participated.

The investor base is narrow compared to most startups at this valuation.

Zoom

Sequoia Capital, Emergence Capital, Horizons Ventures (Li Ka-shing), Qualcomm Ventures